0001209191-18-038422.txt : 20180618 0001209191-18-038422.hdr.sgml : 20180618 20180618191649 ACCESSION NUMBER: 0001209191-18-038422 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180614 FILED AS OF DATE: 20180618 DATE AS OF CHANGE: 20180618 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Popovits Kimberly J CENTRAL INDEX KEY: 0001333482 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51541 FILM NUMBER: 18905790 MAIL ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENOMIC HEALTH INC CENTRAL INDEX KEY: 0001131324 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770552594 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-556-9300 MAIL ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-06-14 0 0001131324 GENOMIC HEALTH INC GHDX 0001333482 Popovits Kimberly J 301 PENOBSCOT DR. REDWOOD CITY CA 94063 1 1 0 0 President and CEO Common Stock 2018-06-04 5 G 0 E 100 0.00 D 59517 D Common Stock 2018-06-14 4 M 0 10000 17.18 A 246157 I Held by the Popovits 2010 Trust Common Stock 2018-06-14 4 S 0 9600 48.8556 D 236557 I Held by the Popovits 2010 Trust Common Stock 2018-06-14 4 S 0 400 49.755 D 236157 I Held by the Popovits 2010 Trust Common Stock 12298 I Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits Common Stock 16825 I Held in trust for the benefit of Ms. Popovits' son, of which Ms. Popovits is trustee. Employee Stock Option (right to buy) 17.18 2018-06-14 4 M 0 10000 0.00 D 2020-02-18 Common Stock 0 57900 D Includes an aggregate of 51,204 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 6, 2017. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. Represents weighted average sale price. Actual sale prices ranged from $48.52 to $49.29. Represents weighted average sale price. Actual sale prices ranged from $49.71 to $49.80. The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter. /s/ Jason W. Radford, Attorney-in-fact 2018-06-18